Zydus Lifesciences (previously Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) for marketing Adapalene and Benzoyl Peroxide Topical Gel, 0.3%/2.5%.

The product is a generic of Epiduo Forte. It is a combination of Adapalene, which is a retinoid, and Benzoyl Peroxide, which is an antibiotic and skin-peeling agent.

Adapalene and Benzoyl Peroxide Topical Gel is used for reducing the number and severity of acne pimples.

While Adapalene works by impacting the growth of cells and reducing swelling and inflammation, Benzoyl Peroxide works by lowering the amount of acne-causing bacteria and by causing the skin to dry and peel off.

Zydus Lifesciences will manufacture Adapalene and Benzoyl Peroxide Topical Gel drug at its topical facility in Ahmedabad.

As per IQVIA MAT on April 22, Adapalene and Benzoyl Peroxide Topical Gel had a market size of $195 million.

  Acne, Adapalene, Ahmedabad, Benzoyl Peroxide, Cadila Healthcare, Epiduo Forte, pimples, US FDA, USA, Zydus Lifesciences